Richardpruen (talk | contribs) (→Suggested studies to add to this page: add switch to vaping text message paper) |
|||
| Line 11: | Line 11: | ||
=Dual Use= | =Dual Use= | ||
===2023: [https://pubmed.ncbi.nlm.nih.gov/38192585/ Varenicline for smoking cessation in individuals who smoke cigarettes and use electronic cigarettes: a double-blind, randomised, placebo-controlled phase 3 trial]=== | |||
*Our findings indicate that inclusion of varenicline in a cessation programme for adults who smoke and use e-cigarettes with an intention to quit smoking could result in smoking abstinence without serious adverse events. In the absence of evidence from other smoking cessation methods, it could be useful to suggest the use of varenicline in cessation programmes specifically designed to help dual users stop smoking. | |||
*Caponnetto P, Spicuzza L, Campagna D, Ahluwalia JS, Russell C, Maglia M, Riela PM, Longo CF, Caci G, Quattropani MC, Signorelli MS, Polosa R. Varenicline for smoking cessation in individuals who smoke cigarettes and use electronic cigarettes: a double-blind, randomised, placebo-controlled phase 3 trial. EClinicalMedicine. 2023 Nov 21;66:102316. doi: 10.1016/j.eclinm.2023.102316. PMID: 38192585; PMCID: PMC10772233. | |||
===2021: [https://www.clivebates.com/documents/NLFlavoursResponseJan2021.pdf Regulation of e-cigarette flavours – a response]=== | ===2021: [https://www.clivebates.com/documents/NLFlavoursResponseJan2021.pdf Regulation of e-cigarette flavours – a response]=== | ||
| Line 29: | Line 33: | ||
**Proposes an illiberal policy and fails to recognise a major global public health opportunity. | **Proposes an illiberal policy and fails to recognise a major global public health opportunity. | ||
*Acknowledgement: We confirm that signatories report no conflicts with respect to FCTC Article 5.3 and no financial conflicts of interest with respect to tobacco or e-cigarette companies under the International Committee of Medical Journal Editors (ICJME) reporting standard. | *Acknowledgement: We confirm that signatories report no conflicts with respect to FCTC Article 5.3 and no financial conflicts of interest with respect to tobacco or e-cigarette companies under the International Committee of Medical Journal Editors (ICJME) reporting standard. | ||
===2020 [https://pubmed.ncbi.nlm.nih.gov/33086157/ A comparison of product dependence among cigarette only, ENDS only, and dual users: Findings from Wave 3 (2015-2016) of the PATH study]=== | ===2020 [https://pubmed.ncbi.nlm.nih.gov/33086157/ A comparison of product dependence among cigarette only, ENDS only, and dual users: Findings from Wave 3 (2015-2016) of the PATH study]=== | ||
edits